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Abstract
Background: Although microRNAs (miRNAs) are implicated in osteosarcoma biology and chemoresponse, miRNA
prognostic models are still needed, particularly because prognosis is imperfectly correlated with chemoresponse.
Formalin-fixed, paraffin-embedded tissue is a necessary resource for biomarker studies in this malignancy with
limited frozen tissue availability.
Methods: We performed miRNA and mRNA microarray formalin-fixed, paraffin-embedded assays in 65
osteosarcoma biopsy and 26 paired post-chemotherapy resection specimens and used the only publicly available
miRNA dataset, generated independently by another group, to externally validate our strongest findings (n = 29).
We used supervised principal components analysis and logistic regression for survival and chemoresponse, and
miRNA activity and target gene set analysis to study miRNA regulatory activity.
Results: Several miRNA-based models with as few as five miRNAs were prognostic independently of pathologically
assessed chemoresponse (median recurrence-free survival: 59 months versus not-yet-reached; adjusted hazards
ratio = 2.90; P = 0.036). The independent dataset supported the reproducibility of recurrence and survival findings.
The prognostic value of the profile was independent of confounding by known prognostic variables, including
chemoresponse, tumor location and metastasis at diagnosis. Model performance improved when chemoresponse
was added as a covariate (median recurrence-free survival: 59 months versus not-yet-reached; hazard ratio = 3.91;
P = 0.002). Most prognostic miRNAs were located at 14q32 - a locus already linked to osteosarcoma - and their
gene targets display deregulation patterns associated with outcome. We also identified miRNA profiles predictive
of chemoresponse (75% to 80% accuracy), which did not overlap with prognostic profiles.
Conclusions: Formalin-fixed, paraffin-embedded tissue-derived miRNA patterns are a powerful prognostic tool for
risk-stratified osteosarcoma management strategies. Combined miRNA and mRNA analysis supports a possible role
of the 14q32 locus in osteosarcoma progression and outcome. Our study creates a paradigm for formalin-fixed,
paraffin-embedded-based miRNA biomarker studies in cancer.
Background
Osteosarcoma is the most common primary bone malig-
nancy, disproportionally affecting children and young
adults [1]. Overall five-year survival rates for newly diag-
nosed osteosarcomas range from 40% to 75% [2]. Standard
treatment consists of two to three rounds of chemother-
apy, followed by definitive resection, and additional adju-
vant chemotherapy. Although pathologically assessed
chemoresponse is a useful surrogate for long-term out-
come, it is not always tightly correlated with recurrence
patterns and survival. Patients whose tumors show high
levels of necrosis following preoperative chemotherapy
have a uniformly good prognosis (up to 90% cure rates)
whereas those with lower levels of necrosis have variable
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Despite work on genetic characterizations of this disease,
there are currently no good biomarkers for osteosarcoma
outcome following standard treatment [3,4]. This has pre-
vented effective recurrence risk stratification and may
explain treatment strategies for osteosarcoma remaining
unchanged for almost 20 years. Previous studies have
reported gene expression profiles associated with chemor-
esponse in human cohorts as well as genes associated with
survival in a dog osteosarcoma model [5-7], thereby pro-
viding important biological insights, but sample limitations
did not allow development of a clinical prognostic signa-
ture for recurrence and survival, which remains an unmet
need.
MicroRNAs (miRNAs) are critical regulators of cancer
biology with a probable role in different sarcomas [8].
Osteosarcoma-focused studies found differentially
expressed miRNAs between osteosarcoma tissue and nor-
mal osteoblasts, and implicated miRNAs in chemoresis-
tance [9-12] or in vitro proliferation and metastasis
[13,14]. A recent study reported miRNAs predictive of
chemoresponse and miRNAs associated with a binary
metastasis endpoint in a human cohort, and provided bio-
logical context for their role [7]. However, to date, human
outcome studies have been limited by small patient sample
sizes (n < 30, a common limitation when studying rare dis-
eases). Thus, a formal gene or miRNA model predictive of
outcomes using human osteosarcoma clinical specimens
has not yet been developed. This effort is further limited
by the rarity of frozen tissue resources, with long-term
outcome annotation suggesting that formalin-fixed, paraf-
fin-embedded (FFPE) tissue may be a critical alternative
resource for such studies.
In the largest osteosarcoma profiling study to date, we
developed miRNA models with independent predictive
value for recurrence and overall survival (OS) from FFPE
human osteosarcoma diagnostic biopsy specimens. Prog-
nostic miRNAs were mainly clustered on a chromosomal
locus recently reported to be linked to osteosarcoma
[10,15]. We utilized the only other publicly available
osteosarcoma miRNA dataset that included outcome
annotations and were able to independently validate the
prognostic value of many of our candidate miRNAs.
Lastly, we performed complementary assessment of che-
moresponse using both static and dynamic paired expres-
sion patterns. Our study sets a paradigm for profiling
studies using FFPE samples in rare tumors.
Methods
Paraffin-based human osteosarcoma cohort
We used 91 FFPE osteosarcoma samples from the pathol-
ogy archives of Beth Israel Deaconess Medical Center and
Boston Children’s Hospital. The cohort included 65 diag-
nostic biopsy specimens and 26 paired surgical resection
specimens (Table 1 and Table S1 in Additional file 1).
A protocol for archival tissue collection was approved by
Institutional Review Board at both institutions with a
waiver of consent.
Formalin-fixed, paraffin-embedded RNA isolation, whole
genome and miRNA profiling, quality control and
processing
FFPE samples were cut into 10 μms e c t i o n s .T o t a lR N A
was isolated using the Qiagen RNeasy FFPE protocol
(Qiagen, Valencia, CA, USA). miRNA expression profil-
ing was performed for all 91 FFPE samples using miRNA
cDNA-mediated annealing, selection, extension and liga-
tion (DASL) assays (Illumina, Hayward, CA, USA), con-
taining probes for 1,146 miRNAs [16,17]. Whole genome
DASL arrays, containing probes for 29,285 transcripts,
were used for profiling all 26 surgical resection speci-
mens in addition to 43 of the biopsy specimens and were
conducted as previously described [18-20]. Assays were
run at the Molecular Genetics Core Facility at Boston’s
Children’s Hospital. The DASL assay is a bead-based
method for expression profiling of degraded RNA, such
as that extracted from FFPE samples [16-24]. Raw
miRNA and mRNA DASL data have been deposited in
the National Center for Biotechnology Information’s
Gene Expression Omnibus [GSE:39058] [25]. Dataset
Table 1 Clinical characteristics of the osteosarcoma
cohort
Characteristic Number (n = 65)
Age, years
a, b
Median 12
Range 3 to 76
Gender
Male 30 (46%)
Female 35 (54%)
Specimens
Biopsy 65
Resection 26
Chemosensitive tumors 32 (49%)
Tumor location
Axial 3
Appendicular 62
Events
Recurrence 23
Death 14
Metastases at diagnosis
No 54
Yes 11
Preoperative chemotherapy
MAP only 42
Other than MAP (for example MAPIE, IE) 23
aTwo patients were over 35 years old;
bone had prior Paget’s bone disease.
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significantly detected (P < 0.01), average signal intensity,
95
th percentile signal intensity and housekeeping gene
signal intensity (Additional file 2). All 91 miRNA assays
passed quality control criteria. There was no correlation
between specimen storage age and quality (Additional
file 2). Of the mRNA expression profiling assays, 42
passed quality control criteria including 37 biopsy speci-
mens and 5 surgical resection specimens. After excluding
failed samples, data were processed by variance stabiliz-
ing transformation and quantile normalization using the
Lumi package in R [26,27]. To minimize noise from
uninformative probes, we filtered out miRNAs with an
expression variance across the cohort in the bottom 33%,
and we filtered out mRNAs with an expression variance
in the bottom 90%.
Computational survival analysis and miRNA activity
methods
Recurrence-free survival (RFS), OS and gene set expres-
sion comparison analyses (GSA) were done using the
National Cancer Institute Biometric Research Branch
ArrayTools software [28,29]. For recurrence and survival
analysis, differentially expressed miRNAs and mRNAs
were identified using standard statistical methods
employed by the software. Risk prediction models were
generated using an implementation of the supervised prin-
cipal components method originally described by Bair and
Tibshirani [30]. miRNA regulatory activity analysis was
performed using an adoption of the regulatory effects
scoring method developed by Cheng et al. [31]. mRNA
data were imported into the R environment and miRNAs
were called as significantly differentially activated if the
regulatory effects scoring was associated with a P-value of
0.05 (false discovery rate (FDR) < 0.1). The script used in
this analysis has been uploaded as Script S1 in Additional
file 3. The miRanda-based GSA target gene algorithm was
implemented on ArrayTools [28,29,32].
Ordinal logistic regression modeling and chemotherapy
response prediction
To take advantage of the ordinal nature of the chemother-
apy response endpoint, we used ordinal logistic regression
(OLR) as our primary mathematical modeling tool:
ln θi = αi −  jβjXj θi =
p

Category ≤ i


1 − p

Category ≤ i
 (1)
P

Z ∈ Category1

=
1
1+e−(α1−

βkXk) (2)
OLR regresses a log-likelihood ratio of one ordered
category versus another on continuous independent
variables - in this case normalized miRNA or mRNA
expression measurements (equation 1) [33] and was
implemented using the Design package in the R environ-
ment [34,35]. In brief, the sample cohort was randomly
split 500 times into training and test sets. After feature
selection, an OLR model was trained using each of the 500
training sets, and predicted probabilities were obtained for
each respective test set (equation 2). A chemoresponse
category was assigned to that with the highest predicted
probability. Multiple univariate OLR models were gener-
ated using up to 20 miRNAs with the highest individual
concordance values and chemotherapy response predic-
tions were assigned based on the geometric means of mul-
tiple OLR model-based predictions. We also attempted
multivariate prediction using a small number of miRNAs
as described in the supplementary methods (Additional
file 2). The scripts used to implement OLR have been
uploaded as Script S2 in Additional file 4 and Script S3 in
Additional file 5.
Results
Osteosarcoma miRNA and mRNA assays
We used 65 FFPE primary osteosarcoma diagnostic biopsy
specimens from the pathology archives at Beth Israel
Deaconess Medical Center and Boston Children’sH o s p i -
tal. We also obtained paired, post-chemotherapy surgical
resection specimens for 26 of these patients (Table S1 in
Additional file 1). miRNA and whole genome DASL assays
were performed as described in the methods section.
miRNA profiles of recurrence and survival in
osteosarcoma
We first sought to identify miRNA and mRNA expression
profiles associated with risk for recurrence and OS. Using
standard univariate Cox proportional hazards models we
identified 25 miRNAs associated with RFS and 31 miRNAs
associated with OS (P < 0.01; Figure 1A and 1B, respec-
tively). The two sets of miRNAs were highly overlapping
and strongly significant when corrected for multiple
testing.
Next, we applied a supervised principal components sur-
vival risk prediction method [30] with 10-fold cross-valida-
tion and a random permutation test. We found several
prognostic models of sizes ranging to at least 25 miRNAs
that performed well. Figure 2A and 2D show two indicative
examples utilizing two different P-value cutoffs for inclu-
sion in the model (P < 0.001 and P < 0.0075) representing
a model with five miRNAs (median RFS: 59 months versus
not-yet-reached, hazard ratio (HR) = 2.66, 95% confidence
interval (CI): 1.123 to 6.303, log rank P =0 . 0 2 ;p e r m u t a t i o n
P = 0.04; Figure 2H), and a model with 22 miRNAs (med-
ian RFS: 126 months versus not-yet-reached, HR = 2.77,
95% CI: 1.025 to 7.475, log rank P = 0.035; permutation
P = 0.11; Figure 2G). Because of a limited number of
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cantly predictive of OS risk; however, several demonstrated
a notable discriminatory trend (Figure 3A).
We repeated the analyses described above using mRNA
data, and we identified 66 genes significantly associated
with recurrence, and 38 associated with OS (Table S2 in
Additional file 6 and Table S3 in Additional file 7; P <
0.05). Unlike the miRNA-based analysis, mRNA expres-
sion-based models for recurrence and survival did not
reach a level of statistical significance likely due to the
smaller sample size for this analysis.
miRNA profiles are prognostic independently of known
prognostic factors
We also tested whether miRNA-based risk prediction is
independently prognostic of recurrence when controlling
for the effect of several known prognostic factors (Table 2).
The additional possible confounding covariates we consid-
ered were anatomic tumor site, chemotherapy response,
presence of metastases at diagnosis, and type of presurgical
chemotherapy.
Anatomic tumor site
Only three of the patients in the cohort presented with
axial tumors whereas the overwhelming majority of
tumors were located in the extremities. Thus, the cohort
was homogeneous with respect to this covariate, which
therefore could not confound the analysis (formal Cox
multivariate regression confirmed this as well, P = 0.764
with 22 miRNA profile; P = 0.666 with 5 miRNA profile).
Chemotherapy response
Chemotherapy response, assessed by the degree of tumor
necrosis in the primary tumor following preoperative che-
motherapy, has been shown to have prognostic value in
osteosarcoma. A multivariate Cox model showed that both
risk prediction with the 5 miRNA and the 22 miRNA pro-
file and chemotherapy response retained their independent
significance (22 miRNA: HR 2.90, P = 0.036; chemotherapy
response: HR 3.82, P = 0.005 and 5 miRNA: HR 2.67, P =
0.026, chemotherapy response: HR 3.70, P =0 . 0 0 6 ) .
Metastases present at diagnosis
We used metastasis at diagnosis alone to perform multi-
variate analysis. Formal multivariate Cox regression
proved that the miRNA prognostic profile retained its
independent prognostic significance when one controls for
the effect of metastatic disease at diagnosis (Table 2). As
expected, presence of metastasis at diagnosis was a power-
ful predictor of outcome. However, multivariate Cox
model also showed that risk prediction based on the 22
miRNA and 5 miRNA prognostic profiles retained inde-
pendent prognostic significance for recurrence (HR = 2.27,
P = 0.115 and HR = 2.40, P = 0.050, respectively).
Type of preoperative chemotherapy
All patients received methotextrate/adriamycin/cisplatin
(MAP)-based chemotherapy with the exception of a few
Figure 1 miRNAs associated with recurrence and survival. miRNAs significantly associated with (A) recurrence and (B) survival (P < 0.01).
Color map displays univariate HRs for recurrence. Bold text denotes miRNAs located at 14q32. FDR, false discovery rate; HR, hazard ratio.
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Page 4 of 12Figure 2 Recurrence risk prediction. (A, D) Kaplan-Meier analysis of recurrence risk (supervised principal components analysis for the 22 and
5 miRNA profiles). (B, E) Kaplan-Meier analysis of recurrence risk for the 22 and 5 miRNA profiles in addition to chemoresponse as a clinical
covariate in the model. (C, F) Kaplan-Meier analysis of recurrence risk using both 22 and 5 miRNA profiles and chemoresponse as categorical
variables (three-group analysis). (G) 22 miRNA profile. (H) 5 miRNA profile.
Figure 3 miRNAs are prognostic of recurrence and survival in an independent external dataset. Our prognostic miRNAs were used to
generate models of OS in an independent external validation dataset. Of the 22 miRNA profile, 18 miRNAs could be mapped on the platform
used in the external dataset. (A-C) These overlapping miRNAs (as well as smaller subsets of this profile) were used to generate survival risk
prediction models. A consistent discriminatory trend was observed in the external dataset, despite a smaller sample size, fewer events and
different array platform.
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per standard treatment convention. However, a subset of
patients received variant regimens of MAP (mainly MAP/
IE (ifosfomide/etoposide)). We found that treatment with
am o r e‘aggressive’ regimen was entirely confounded by
and highly correlated with whether the patient presented
with metastases at diagnosis (Fisher’s P < 0.001) and did
not confer any prognostic value for outcome when
adjusted for metastasis at diagnosis. Therefore, there was
no need to additionally control the prognostic value of
miRNA profile for this covariate.
To further illustrate the independent prognostic value of
the profile we performed Kaplan-Meier analyses restricted
to two separate homogeneous subsets of patients, who had
non-metastatic disease at diagnosis or who received only
MAP chemotherapy. We found that the miRNA profile
still retained impressive prognostic power in these homo-
geneous cohorts, again discriminating between a high and
low risk group (median RFS 151 months versus not
reached, log rank P=0.035; and median RFS 151 months
versus not reached, log rank P = 0.026; Figure 4A and 4B,
respectively).
We reasoned that miRNA risk assessment and chemore-
sponse may be synergistically prognostic. When chemore-
sponse was incorporated with the 22 miRNA and
5 miRNA profiles into multivariate models, risk discrimi-
nation improved (median RFS: 59 months versus not-yet-
reached; HR = 4.96, 95% CI: 1.830 to 13.446, Figure 2B;
and median RFS: 59 months versus not-yet-reached; HR =
3.91, 95% CI: 1.533 to 9.956, Figure 2E). We then created
a categorical variable taking three possible values: ‘poor,’
‘intermediate’ and ‘good.’ Patients were classified as ‘poor’
if they had an unfavorable chemotherapy response and a
high-risk miRNA profile. ‘Intermediate’ patients had either
a high predicted risk of recurrence, or an unfavorable che-
motherapy response, but not both. Finally, ‘good’ patients
had both a low predicted risk of recurrence, and a favor-
able chemotherapy response. Kaplan-Meier analysis with
this new categorical variable demonstrated a strikingly
poor prognosis for patients in the ‘poor’ category, and sig-
nificantly better prognoses for both the ‘intermediate’ and
‘good’ patients (log rank P < 0.001, Figure 2C, F).
The combined power of miRNA expression and che-
motherapy response as a clinical covariate was also evident
in analyzing OS. miRNA expression levels, taken alone,
could not generate statistically significant survival predic-
tion models (HR = 1.65, log rank P = 0.365; Figure S1A in
Additional file 8). Although this analysis was possibly lim-
ited by a small number of deaths, chemotherapy response
was predictive of survival (Figure S1B in Additional file 8).
However, a combined model using supervised principal
components regression identified miR-495 (one of the five
miRNAs from the prognostic profile) as significantly add-
ing prognostic power to a model using chemoresponse
alone. The combined model including chemoresponse and
miR-495 expression showed a very strong discriminatory
capacity, despite the limited number deaths in our cohort,
(median OS: 82 months versus not-yet-reached, HR =
8.26, 95% CI: 1.820 to 37.435; log rank P < 0.001; permuta-
tion P = 0.11; Figure S1C in Additional file 8). Further
refinement of a model for OS would require a future study
with a larger sample size.
Independent external dataset supports the prognostic
value of candidate miRNAs for recurrence
Jones and colleagues recently published an independent,
publicly available miRNA dataset [7]. Using their dataset,
they studied miRNAs relevant to chemoresponse, investi-
gated their biological role, and provided analysis of meta-
static outcome based on a more limited sample size (n =
29, 10 recurrences). There were substantial differences
between this dataset and ours, namely its source (frozen
tissue specimens), array platform (Agilent), smaller sam-
ple size and event number, and the fact that metastasis
was reported as a binary, not time-censored, outcome.
However, we performed Cox regression analysis on mar-
ker miRNAs included in our 22-miRNA profile, of which
only 18 were present on the Agilent array. Of those 18,
we found 8 associated with recurrence in the indepen-
dent dataset with a significant P-value (P <0 . 0 5 )o ra
trend to significance (P < 0.1). Given the sample size and
other limitations of this comparison, this finding is signif-
icant as confirmed by a simulation analysis testing 100
random lists of 18 miRNAs from the independent dataset
that found that only 4 out of 100 contained 8 of the 18
significant miRNAs at the same statistical level (permuta-
tion P = 0.04), demonstrating that the significance level
of our miRNAs in the independent dataset is very unli-
kely due to chance. We attempted to further use the lim-
ited number of deaths in that dataset (n = 7), which were
reported as a time-censored outcome, and despite the
challenge of such a small event number, we were able to
generate several models using our prognostic genes
showing strong discriminato r yc a p a c i t yf o rs u r v i v a l ,
although their P-values did not reach nominal signifi-
cance due to very limited power (Figure 3).
Table 2 Multivariate analysis of the miRNA prognostic
power adjusting for the effect of known prognostic
factors
Univariate hazard
ratio
(5 miRNA profile)
P Multivariate hazard ratio
(5 miRNA profile)
P
2.66 (1.12 to 6.30) 0.02 Controlling for chemoresponse 2.67 0.026
Controlling for metastases at
diagnosis
2.40 0.05
Tumor site was not prognostic due to the overwhelming majority of tumors
located in the extremities, and preoperative chemotherapy regimen was
confounded by the presence of metastasis at diagnosis.
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activity analysis of prognostic miRNAs
Interestingly, we observed that a majority of the top
miRNA prognostic markers (four from the 5 miRNA pro-
file and fifteen from the 22 miRNA profile) were located
at chromosome 14q32. This locus has been associated
with Paget’sb o n ed i s e a s e[ 3 6 ] ,w h i c hi sak n o w ns t r o n g
risk factor for osteosarcoma. At least 10 miRNAs poten-
tially involved in osteosarcoma at 14q32 have been
reported [10,15]. However, this locus has not previously
been associated with clinical outcome.
Previous work has shown that additional insights into
the role of miRNAs can be gained by examining their reg-
ulatory activity in terms of effects on target mRNAs
[31,37]. Therefore, in a separate analysis of the whole gen-
ome DASL data, we explored the association of prespeci-
fied gene sets of miRNA targets with recurrence and
survival using complementary methods. Using the miR-
anda algorithm to obtain target gene sets and an estab-
lished gene set analysis method [31,38], we found a
number of miRNA-regulated gene sets demonstrating
association with recurrence (P < 0.05; Table 3). We also
conducted this analysis using the regulatory effects scoring
method [31] and identified several miRNAs with signifi-
cantly different regulatory activity associated with recur-
rence and survival endpoints (Table 3; P < 0.05, FDR <
0.1). Strikingly, among the significant gene sets, some were
regulated by miR-411*, miR-379*, miR-539, miR-616*,
miR-493*, miR-323-3p and miR-382, which were prognos-
tic of recurrence when their expression levels were
assessed. This finding suggests that not only miRNA
expression levels but also their target genes (collectively)
are associated with outcome by way of deregulation.
We explored several aspects of the association of the
miRNA target genes with outcome. Thirty of the genes
targeted by these miRNAs were significantly differentially
expressed between the high and low risk groups as defined
by the miRNA expression profile (t-test P < 0.05; Table S4
in Additional file 9). Furthermore, we performed unsuper-
vised hierarchical clustering of the tumor diagnostic
biopsy specimens using the expression levels of the gene
targets of the prognostic miRNAs. We observed two main
clusters, each of them including preferentially high-risk or
low-risk samples as defined in the prognostic analysis
using the 22 miRNA and 5 miRNA profiles’ expression
levels (Fisher’s exact test P-value 0.005 and 0.003, respec-
tively). We also performed supervised recurrence risk pre-
diction analysis and identified a profile consisting of a
subset of mRNAs (miRNA gene targets) that showed a
strong trend in distinguishing good and poor prognosis
tumors, although not as strongly as the miRNA levels
themselves - probably as a result of a smaller sample size
in this analysis (n = 37, median RFS 28 months versus
not-yet-reached, log rank P = 0.260; Figure 4C). Interest-
ingly, PDE4PIP, the top predictor gene in this prognostic
analysis, appeared to be targeted by multiple prognostic
miRNAs, potentially strengthening the specificity of a bio-
logical hypothesis. These findings, taken together, suggest
that at least some of the 14q32 prognostic miRNAs
together with several of their target genes may also be ele-
ments of a deregulated circuit with biological significance
in osteosarcoma progression and outcome. Further biolo-
gical studies are needed, which are beyond the scope of
this prognostic study, to further validate these interesting
observations and elucidate the full extent of biological sig-
nificance of these miRNAs in osteosarcoma.
Chemotherapy response prediction in pretreatment
biopsies and expression changes in post-chemotherapy
resection specimens
We analyzed chemoresponse as an ordinal binary variable
(’optimal’ versus ‘suboptimal’ response defined as the
Figure 4 Recurrence risk prediction in relevant homogeneous patient subsets and using miRNA gene targets. (A) Kaplan-Meier recurrence
analysis with the five miRNA profile in the non-metastatic (only) subset of the cohort. (B) Kaplan-Meier recurrence analysis with the five miRNA profile
in the subset of patients that received MAP (only). (C) Kaplan-Meier recurrence analysis using a subset of gene targets of prognostic miRNAs.
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assessed by an expert pathologist) using OLR (Figure S2 in
Additional file 10). We took the approach of averaging the
predictions from the top univariate OLR models, to reduce
the chance of serious over-fitting (average univariate pre-
diction; AP). We discovered a range of miRNA signatures
(five to ten miRNAs) that predict for optimal chemore-
sponse with approximately 75% accuracy (averaged over
multiple random training/test set splits of different sizes;
Figure S3A in Additional file 11, Figure S4A in Additional
file 12, and Figure S5 in Additional file 13). The miRNAs
i nt h ec h e m o r e s p o n s ep r o f i l ew e r ee n t i r e l yn o n - o v e r l a p -
ping with the miRNAs in the recurrence/survival profile,
underscoring the notion that mechanisms of resistance to
conventional chemotherapy may be distinct from mechan-
isms determining overall outcome. There were 27 miR-
NAs significant at the 0.05 level and the concordance
values of the five to ten top univariate models ranged
between 0.67 and 0.76 (Table S5 in Additional file 14).
The stability of the predictor miRNA list was assessed in
multiple random subsets of the dataset as described in the
methods section [39]. We then attempted multivariate
ordinal logistic modeling. This analysis was limited by
sample size, but we found that a two-miRNA multivariate
model performed almost as well as the optimal averaged
univariate models (Figure S3B in Additional file 11). No
improvement in predictive accuracy was obtained with
mRNA models or combined miRNA and mRNA models.
We further performed an exploratory miRNA expres-
sion analysis of 26 paired pre- and post-chemotherapy
specimens and we observed many expression changes
following exposure to chemotherapy (70 miRNAs differ-
entially expressed), which were non-overlapping with
the predictive or prognostic profiles described above.
This exploratory analysis is described in the Additional
file 15 and Table S6 in Additional file 16 and will
require further validation in future studies.
Discussion
Combined modality treatment in osteosarcoma has led to
survival gains and fewer amputations, but outcomes have
remained unchanged for over 20 years [2,40]. Adoption
of novel therapies is complicated by the lack of reliable
means to prognostically stratify patients. Even though it
is a useful surrogate, pathologically assessed chemother-
apy-induced tumor necrosis assessed at the time of defi-
nitive resection, the only accepted prognostic variable, is
imperfectly correlated with distant outcome especially for
sub-optimally responsive patients [2,41]. Genome-wide
s t u d i e sh a v ep r o v i d e dv a l u a b l ed a t ao nc h e m o r e s p o n s e
[5-7,42,43] but there have been no studies examining
miRNA and mRNA expression profiles using continuous
time-censored recurrence and survival as endpoints.
Given the rarity of well-annotated frozen tissue reposi-
tories, we sought to develop clinical outcome predictors
using FFPE tissue. Our successful attempt implies clinical
applicability, and establishes FFPE tissue as an appropri-
ate substrate for such studies in osteosarcoma, particu-
larly for miRNA profiling.
We found a strong relationship between miRNA expres-
sion profiles and RFS, the first such observation in this dis-
ease. Using established methods [30], we developed several
models predictive of recurrence independent of che-
motherapy response, although future development would
naturally focus on the smaller, simpler models (for exam-
ple, the five miRNA profile; Figure 2H). We also demon-
strated that miRNA models are prognostic independent of
potential confounding by known prognostic factors, such
as chemoresponse, tumor location, presence of metastasis
at presentation or chemotherapeutic regimen variation
Table 3 Differential regulatory activity of prognostic miRNAs on the 14q32 locus
Differentially activated miRNA Gene target prediction Activity/enrichment assessment P
hsa-miR-758 TargetScan RE score 0.031
hsa-miR-299 TargetScan RE score 0.034
hsa-miR-299-3p TargetScan RE score 0.034
hsa-miR-493 Pita RE score 0.022
hsa-miR-323-5p Pita RE score 0.025
hsa-miR-411* miRanda GSA 0.005
hsa-miR-379* miRanda GSA 0.020
hsa-miR-139-5p miRanda GSA 0.005
hsa-miR-539 miRanda GSA 0.047
hsa-miR-616* miRanda GSA 0.010
hsa-miR-493* miRanda GSA 0.025
hsa-miR-323-3p miRanda GSA 0.010
hsa-miR-382 miRanda GSA 0.040
Using the regulatory effects scoring method with three different miRNA target prediction algorithms and miRanda-based GSA analysis, differentially activated
miRNAs associated with recurrence were identified. Listed are those differentially activated miRNAs at 14q32 whose expression levels are associated with
recurrence (P < 0.05). GSA, Gene Set Expression comparison Analyses; RE, Regulatory Effect
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prognostic in osteosarcoma to this date). Interestingly, risk
prediction improved when chemotherapy response and
miRNA risk profiles were combined, suggesting that che-
mosensitivity and miRNA profiles capture non-redundant
prognostic information. Indeed, many patients in our
cohort who did not respond optimally to chemotherapy
either had no recurrence, or had recurrent disease after a
long remission. These findings are highly relevant to clini-
cians wishing to provide robust prognostic information
and prioritize patients for different or novel treatment
approaches. For example, the largest ongoing randomized
study in osteosarcoma (AOST0331, targeting 1,400
patients worldwide) is studying the modification of che-
motherapy postoperatively, in the case of suboptimal
response to preoperative chemotherapy. Thus the impetus
to incorporate powerful marker profiles, non-overlapping
with chemotherapy response, for improved patient risk
stratification is increasing. The prognostic association
between miRNA profiles and OS was weaker, however the
power of this secondary analysis was limited by a smaller
number of events (deaths) and we still detected potential
prognostic synergy between miRNAs and chemoresponse
with respect to OS. A larger future study will allow a more
definitive prognostic analy s i sw i t hr e s p e c tt oO St ob e
performed.
In addition to a stringent internal cross-validation, we
achieved external validation using the only other public
miRNA dataset that recently reported outcome data [7].
Although widespread differences between the two studies
were challenging (FFPE versus frozen tissue, DASL ver-
sus Agilent array platform, continuous time-censored
versus binary recurrence outcome, and few events), we
were nonetheless able to independently validate the prog-
nostic value of a large subset of miRNAs from our pre-
dictive models and were able to develop signatures, using
these miRNAs (preselected from our discovery set) with
impressive survival distinction, using death as an end-
point. Future studies with larger sample sizes and stan-
dardized platforms will take the next step to assess the
wider reproducibility and performance of a fully specified
model. However, these studies will require a long time to
assemble multiple adequately sized tumor cohorts in
such a rare disease. Thus, our data provide strong and
necessary initial evidence supporting the wider reprodu-
cibility of prognostic miRNA profiles in osteosarcoma.
Some of our profile miRNAs have been previously
reported [10,15] but not in association with osteosarcoma
clinical outcome. These were predominantly located at
14q32 in the genome - a locus associated with osteosar-
coma and Paget’s disease (a known risk factor for osteo-
sarcoma) - strengthening the biological plausibility of our
results. It has been suggested that rearrangements of
chromosome 14 may play a role in altered miRNA
expression in osteosarcoma [10]. Because miRNA target-
genesets of some of 14q32 prognostic miRNAs were also
associated with outcome, potentially indicating miRNA
activation, our data suggest that this genomic locus may
have a significant role in osteosarcoma progression and
outcome. Although reports in other tumor systems have
suggested a proliferative and pro-invasive role [44],
further studies are needed to characterize the precise
mechanism by which some of these miRNAs may modu-
late outcome.
We also investigated the relevance of miRNAs to che-
motherapy response and identified novel miRNA signa-
tures predictive of chemosensitivity. These signatures are
largely non-overlapping with overall recurrence and survi-
val profiles, supporting the notion that chemoresponse
and tumor progression and metastasis may be regulated
by non-overlapping molecular networks. We also per-
formed a ‘dynamic’ analysis, revealing miRNA expression
changes following chemotherapy in ‘resistant’ samples
(those with viable tumor at the time of resection).
Although this analysis is exploratory and requires further
validation in a larger study with additional controls, it is
interesting to note that some of the miRNAs identified in
this dynamic analysis - for instance miR-15b, and miR-132
- have also previously been reported in relation to chemor-
esponse [7,11], which is consistent with our results.
mRNA profiles were weaker and did not show additive
value. This was possibly due to a smaller sample size
(fewer samples run on whole genome expression assays
than miRNA assays) and/or unique susceptibility to
mRNA damage in FFPE osteosarcoma tissues (compared
to miRNA stability) related to the fixation or decalcifica-
tion process, which might have blunted the biologic signal.
Nonetheless, miRNA and mRNA prognostic synergy
should be explored more efficiently in future larger stu-
dies. Another possible limitation of our study is the inclu-
sion of adult together with pediatric cases. However, only
two patients were older than 35 years, making it very unli-
kely that their potential biologically unique nature affected
our results.
Conclusions
We present the largest archival osteosarcoma profiling
study to date. We discovered prognostic miRNA signa-
tures with high discriminatory capacity, independent of
and potentially synergistic with traditional chemoresponse
assessment, and provided new insights into the molecular
networks associated with response and exposure to che-
motherapy. Many outcome-related miRNAs display regu-
latory activity changes related to outcome and share a
common genomic locus at 14q32, which has been pre-
viously implicated in osteosarcoma. These findings set the
Kelly et al. Genome Medicine 2013, 5:2
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Page 9 of 12stage for studying a sequential prognostic and predictive
approach, whereby patients are stratified early based on
miRNA profiles at the time of diagnosis, and prognosis is
then refined by subsequent pathologic assessment of che-
moresponse, potentially with additional contribution from
dynamic patterns of miRNA expression in resistant
tumors. Finally, our work serves as a model for FFPE
systems-based translational and clinically applicable geno-
mic research in rare malignancies with limited tissue
availability.
Additional material
Additional file 1: Table S1: Detailed clinical characteristics of cohort.
Chemosensitivity-based prognosis in this table is based on
chemotherapy-induced tumor necrosis of higher than 80%. Additional
relevant clinical characteristics for the cohort are also provided. An
asterisk indicates that a paired, post-chemotherapy specimen also exists
for this patient.
Additional file 2: Supplementary methods. Additional details of the
methodology are presented.
Additional file 3: Script S1. Regulatory Effects Scoring Script. The R
script used to run the microRNA regulatory effects scoring algorithm
described in the methods section.
Additional file 4: Script S2. Average Chemoresponse Prediction
Script. The R script used to run chemotherapy response prediction
analysis using the average univariate prediction method described in the
methods.
Additional file 5: Script S3. Multivariate Chemoresponse Prediction
Script. The R script used to run chemotherapy response prediction
analysis using the multivariate modeling method described in the
methods.
Additional file 6: Table S2. mRNAs associated with recurrence.
mRNAs significantly associated with recurrence at the 0.05 level are
shown along with FDR, a P-value based on random permutations of the
data, and a univariate HR.
Additional file 7: Table S3. mRNAs associated with survival. mRNAs
significantly associated with survival at the 0.05 level are shown along
with FDR, a P-value based on random permutations of the data, and a
univariate HR.
Additional file 8: Figure S1. Survival risk prediction of five miRNA
profile and chemoresponse. (A) Kaplan-Meier analysis of survival for
the five miRNA profile only. (B) Kaplan-Meier analysis of survival for
chemoresponse only. (C) Kaplan-Meier analysis of survival based on miR-
495 expression (the miRNA with the strongest parametric P-value)
combined with chemoresponse as a clinical covariate.
Additional file 9: Table S4. mRNAs differentially expressed across
the good and poor prognostic groups. mRNAs significantly
differentially expressed across the good and poor prognostic groups at
the 0.05 level are shown along with FDR, a P-value based on random
permutations of the data, and fold change.
Additional file 10: Figure S2. Comparison of chemosensitivity
definition metrics. These Kaplan-Meier plots demonstrate that the
clinically accepted prognostic cutoff for chemotherapy-induced tumor
necrosis of 90% performed no better than a cutoff of 80% in predicting
risk for recurrent disease for our cohort.
Additional file 11: Figure S3. Predictive modeling of chemotherapy
response with miRNA data. Mean prediction accuracies across 500
iterations of randomly selected training and test sets using (A) the AP
method with miRNA data, and (B) the multivariate modeling prediction
method using miRNA data.
Additional file 12: Figure S4. Predictive modeling of chemotherapy
response. Mean prediction accuracies across 500 iterations of randomly
selected training and test sets using (A) the AP method with mRNA data,
and (B) the multivariate modeling prediction method using mRNA data.
Additional file 13: Figure S5. Distribution of accuracies for
chemosensitivity prediction. The example shown is for the AP method
using five miRNAs. The distribution of predictive accuracies is shown for
(A) 500 iterations of 95/05 (percent of cohort used in training set/percent
of cohort used in test set) random splits, and (B) 500 iterations of 90/10
random splits.
Additional file 14: Table S5. miRNAs and mRNAs associated with
chemosensitivity. miRNAs and mRNAs univariately significant at the 0.05
level are shown along with regression statistics. The stability of these
top-ranking associated features is reported as a fraction of random
subsets of the data in which the highly ranked feature remains highly
ranked.
Additional file 15: Supplementary results. Additional results of the
study are presented.
Additional file 16: Table S6. miRNA expression profile changes
following chemotherapy. These miRNAs were found to be significantly
differentially expressed at the 0.001 level between paired, pre- and post-
chemotherapy tumor samples.
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